• Citer

Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy

par De Cock, Emile ;Hutton, John;Canney, Peter;Body, Jean-Jacques ;Barrett-Lee, Peter;Neary, M.P.;Lewis, Gavin
Référence Supportive care in cancer, 13, 12, page (975-986)
Publication Publié, 2005-12

Article révisé par les pairs

• Détails
• Contenu

Titre:	Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy
Auteur:	De Cock, Emile; Hutton, John; Canney, Peter; Body, Jean-Jacques; Barrett-Lee, Peter; Neary, M.P.; Lewis, Gavin
Informations sur la publication:	Supportive care in cancer, 13, 12, page (975-986)
Statut de publication:	Publié, 2005-12
Sujet CREF:	Sciences bio-médicales et agricoles
Mots-clés:	Cost-effectiveness
	Ibandronate
	Metastatic bone disease
	Skeletal-related events
	Zoledronic acid
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0941-4355
	info:doi/10.1007/s00520-005-0828-1
	info:scp/27744466365
	info:pmid/15871033